UNASSIGNED: To investigate the impact of antithrombotic medical therapy on recurrence of PVS after PV angioplasty.
UNASSIGNED: A retrospective study of patients undergoing PV angioplasty with or without stent implantation in two German centers was performed. Postinterventional antithrombotic therapy consisted of either dual antiplatelet therapy (DAPT) or a combination of oral anticoagulation with single or dual antiplatelet therapy for 3-12 months after intervention. Angiographic follow-up was recommended 3, 6, and 12 months after intervention and in case of symptom recurrence.
UNASSIGNED: Thirty patients underwent treatment of 42 PVS. After intervention, twenty-eight patients received triple therapy and 14 patients received dual therapy/DAPT; restenosis occurred in 5/22 (22.7%) patients with triple therapy and 8/14 (57.1%) patients with dual therapy/DAPT PV (p = .001). Estimated freedom from PV restenosis after 500 days was 18.8 ± 15.8% (dual therapy/DAPT) and 76.2 ± 10.5% (triple therapy) (p = .003). Univariate regression analysis revealed postprocedural medication as a significant risk factor for restenosis (p = .019). No bleeding events occurred regardless of applied antithrombotic therapy.
UNASSIGNED: Triple antithrombotic therapy after PV angioplasty is associated with less frequent restenosis as compared to dual antiplatelet therapy or a combination of anticoagulation and single antiplatelet therapy. No severe bleeding events occurred in patients on triple therapy. These findings need to be confirmed in larger patient cohorts.
UNASSIGNED:探讨抗血栓药物治疗对PV血管成形术后PVS复发的影响。
UNASSIGNED:在德国的两个中心进行了一项回顾性研究,研究对象是接受PV血管成形术伴或不伴支架植入的患者。介入后抗血栓治疗包括双重抗血小板治疗(DAPT)或口服抗凝与单一或双重抗血小板治疗的组合,干预后3-12个月。建议在干预后3、6和12个月以及症状复发后进行血管造影随访。
未经授权:30例患者接受了42例PVS的治疗。干预后,28例患者接受三联疗法,14例患者接受双联疗法/DAPT;5/22(22.7%)例患者接受三联疗法,8/14(57.1%)例患者接受双联疗法/DAPTPV(p=.001)发生再狭窄.500天后肺静脉再狭窄的估计自由为18.8±15.8%(双联疗法/DAPT)和76.2±10.5%(三联疗法)(p=.003)。单因素回归分析显示术后药物治疗是再狭窄的重要危险因素(p=0.019)。无论应用抗血栓治疗,均未发生出血事件。
UNASSIGNED:与双重抗血小板治疗或联合抗凝和单一抗血小板治疗相比,PV血管成形术后三重抗血栓治疗的再狭窄频率较低。三联疗法患者未发生严重出血事件。这些发现需要在更大的患者队列中得到证实。